By LifETIME CDT Student: Hannah Lamont (University of Birmingham) Going into my PhD project, I knew little about glaucoma and how exactly it’s become the leading cause of irreversible blindness worldwide. Now, a year into my project and I’m completely fascinated by this disease and where exactly the crux of the problem lies; in two …
By LifETIME CDT Administrator: Emma Lardner (University of Birmingham) Delegates have attended the first virtual LifETIME CDT Student Day event bringing together academics, industry partners and LifETIME students. The event began with a welcome from Ivan Wall, Professor of Regenerative Medicine, Cell & Gene Therapy Bioprocessing at Aston University who gave an informative overview of the …
By LifETIME CDT Student: Elena Mandrou (University of Glasgow) My project revolves around studying a signalling pathway that previous research showed it is important for the directional metastasis (or spread) of aggressive cancers. The signal in question is a lipid called lysophosphatidic acid (or LPA) that exists in the cells’ surroundings. The cells’ have a …
By LifETIME CDT Student: Lydia-Styliani Marinou (University of Glasgow) Once upon a time, the Lifetime CDT collaborated with the following CDTs and the UK Society of Biomaterials to organise a joint event this summer: EPSRC-SFI Joint CDT in Engineered Tissues for Discovery, Industry and Medicine (LifETIME) EPSRC/MRC CDT in Regenerative Medicine EPSRC/MRC CDT in Regenerative …
By LifETIME CDT Student: Megan Boseley (Aston University) As part of the CDT coronavirus online training the Dragons Den competition, including the 5 preliminary business and marketing sessions, were pushed forward and moved to zoom. Initially, informative training with Peter Childs and Frank Rinaldi provided background on market awareness, IP, spin-outs and start-ups, forming a …
By LifETIME CDT Student: Eileen Reidy (NUI Galway) Introduction: Colorectal cancer is one of the leading causes of cancer related deaths. Currently patients diagnosed with advanced colorectal cancer have poor 5-year survival rates. Surgery and/or chemotherapy often do not benefit these patients. Due to the complexity and diversity of late stage colorectal cancer, the effects …